2024年 · 第47卷第08期

A total of 4 expert consensus articles have been published in the "Diagnosis and Treatment Plan" column in this issue, which deserves the attention of readers.

Symptomatic malignant pleural effusion (MPE) can be alleviated by thoracic catheter drainage (IPC) or pleurodesis, which requires high medical services and medical costs, but there are not many cost-effectiveness related studies related to these management measures. The study aimed to compare the use of medical services and the cost of home care services after IPC versus hospitalization after pleurodesis in patients with MPE at 12 months after IPC or pleurodesis.

In the manuscript "Tumor Microenvironment Characteristics and Treatment Progress of Malignant Pleural Effusion" published in the review column of Issue 7 of this journal in 2024, the content of the original table "Table 1 Clinical Trials Targeting Tumor Microenvironment Immune Cells or Cytokines" is wrong, and the original header "Local Treatment Progress" should be "Local Treatment Plan"; In the column of registration number and phase in the form, the corresponding registration number and phase in the first line should be: "NCT04749602 (Phase IB/II)"; The corresponding registration number and phase in line 2 shall be: "NCT02942043 (Phase II)"; The corresponding registration number and phase in line 3 shall be: "NCT02250118 (Phase I)"; The corresponding registration number and phase in line 4 shall be: "NCT02054052 (Phase II)"; The corresponding registration number and phase in line 5 shall be: "NCT02054078 (Phase II)"; The corresponding registration number and phase in line 6 shall be: "NCT01661790 (Phase III)"; The corresponding registration number and phase in line 7 shall be: "NCT01327235 (Phase II)"; The corresponding registration number and installment in line 8 shall be: "NCT04131231"; The corresponding registration number and installment in line 9 shall be: "NCT04834830"; The corresponding registration number and phase in line 10 shall be: "NCT02005120 (Phase II)"; The corresponding registration number and phase in line 11 shall be: "NCT05330065 (Phase IB/II)"; Line 12 corresponds to the registration number and phase "NCT05477927 (Phase IA/IB)".